About 10 results found for searched term "K-858" (0.159 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5650 | Fluconazole | Cytochrome P450 (e.g. CYP17) |
| UK 49858 | ||
| Fluconazole is a fungal lanosterol 14 alpha-demethylase inhibitor, which thereby prevents the formation of ergosterol,used in the treatment and prevention of superficial and systemic fungal infections. | ||
| M7876 | K-858 | Kinesin |
| Racemic | ||
| Eg5 is a key protein involved in the formation of bipolar spindles. | ||
| M28183 | GSK5852 | Anti-infection |
| GSK2485852 | ||
| GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively. | ||
| M4937 | Icotinib Hydrochloride | EGFR/HER2 |
| BPI-2009H | ||
| Icotinib Hcl(BPI-2009H) is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R). | ||
| M43838 | Almonertinib mesylate | EGFR/HER2 |
| HS-10296 mesylate | ||
| Almonertinib mesylate is an orally active, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR sensitization and T790M resistance mutations, and also shows strong inhibitory activity against T790M, T790M/L858R, and T790M/Del19, with IC50 of 0.37, 0.29, and 0.21 nM, respectively. The IC50 of T790M/Del19 was 0.37, 0.29 and 0.21 nM, respectively, but the inhibitory effect on wild-type was weaker, with an IC50 of 3.39 nM. It can be used in the research of non-small cell lung cancer. | ||
| M10475 | Lifirafenib (BGB-283) | Raf |
| Beigene-283 | ||
| Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant. | ||
| M14134 | Rociletinib hydrobromide | EGFR/HER2 |
| CO-1686 hydrobromide; AVL-301 hydrobromide; CNX-419 hydrobromide | ||
| Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. | ||
| M14871 | Gefitinib-based PROTAC 3 | PROTAC |
| Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a von Hippel-Lindau ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively. | ||
| M29467 | EGFR-IN-7 | EGFR/HER2 |
| TQB3804 | ||
| EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 can be used for the research of various cancers. | ||
| M31419 | JNJ-28583113 | TRP Channel |
| JNJ-28583113 is a brain-permeable TRPM2 antagonist and blocks phosphorylation of GSK3α and β subunits by inhibiting TRPM2. In addition, JNJ-28583113 inhibits cytokine release from microglia in response to pro-inflammatory stimuli. It has the function of protecting cells from oxidative stress-induced cell death. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
